Comorbid anxiety is common in patients with bipolar disorder. This comorbidity is associated with increased disease severity and poorer treatment response. A study with lurasidone 20-60 mg/day showed significant efficacy against depressive and anxiety symptoms, regardless of baseline anxiety level.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- SURPASS-CVOT
Tirzepatide versus Dulaglutide in T2D with ASCVD
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?
New study on atrial fibrillation in high-risk patients
- Planning a Family, Pregnancy, and Breastfeeding